1. Background {#sec1-1}
=============

Schizophrenia is a serious mental disorder with an unknown etiology and negative symptoms are one of the most difficult areas in the treatment of schizophrenia.^\[[@ref1],[@ref2]\]^ The classic first generation of antipsychotic drugs has little treatment effect on negative symptoms and the second generation of antipsychotics also fails to show better treatment effect on negative symptoms.^\[[@ref3],[@ref4]\]^ Recent research has also been looking for a combined medication method such as antidepressants acting on the 5-HT system, anticholinergic drugs, glycine regulatory drugs, antiepileptic drugs and central stimulants, as well as others for treating negative symptoms. However, the research results were inconclusive.^\[[@ref5]\]^ Non-drug therapy such as psychotherapy also failed to show efficacy for treating negative symptoms.^\[[@ref6]\]^ Repetitive transcranial magnetic stimulation (rTMS) is a new technique of cerebral cortex stimulation developed in recent years. 1.5 \~ 2 Tesla magnetic pulses can pass through the skull without attenuation and produce induction currents in the neural tissues of the superficial layers of the cerebral cortex. This current, as a result, affects the function of the nerve cells (excitatory or inhibitory) and induces therapeutic effect through the changes in neurotransmitter transmission of synaptic, local regional blood flow, nerve repair, and so forth.^\[[@ref7]\]^

In basic research, it is believed that negative symptoms are mainly related to dopamine (DA), reduction of the function of noradrenaline, and the enhancement of the function of 5-hydroxytryptamine (5HT).^\[[@ref8]\]^ The dopamine hypothesis suggested that neural pathways hypofunction of the frontal cortex mediated mainly by the D1 receptor was related to the negative symptoms of patients.^\[[@ref7]\]^ Studies have shown that rTMS can cause changes in a variety of neurotransmitters including dopamine, 5-hydroxytryptamine, glutamate, and so forth. For instance, animal and human experiments found that rTMS on the frontal lobe caused an increase in DA release in the basal ganglia and there was obvious influence on a variety of receptors such as 5-hydroxytryptamine as well as the gene expression that regulated neuronal excitability in different brain regions,^\[[@ref9]\]^ and it was speculated that the projection fibers (cortex- striatal fibers) from the cortex to basal ganglia could release DA.^\[[@ref10],[@ref11]\]^ High frequency magnetic stimulation has certain effect on the regulation of cerebral blood flow velocity.^\[[@ref12],[@ref13]\]^ Based on the results above, some scholars have explored the clinical effect of rTMS on negative symptoms. Cohen and colleagues reported the treatment of rTMS on negative symptoms. The study was a small open sample that showed a significant reduction in negative symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) after 2 weeks of treatment with 20 Hz of rTMS (80% MT).^\[[@ref14]\]^ Up to now, there are already multiple parallel randomized controlled trials with relatively large sample sizes in addition to the relevant published systematic reviews, however, the results are still inconclusive. Some research suggested that rTMS failed to improve negative symptoms.^\[[@ref15]\]^ However, some research suggested that it could improve the efficacy of drug therapy.^\[[@ref18]\]^ And in the past few years there have been more controlled trials and clinical studies with larger sample sizes done using this new treatment mode.^\[[@ref21]\]^ Therefore, this study searched for randomized controlled trails (RCTs) that used rTMS for reducing the negative symptoms of patients with schizophrenia in the published Chinese and English literature. Moreover, the results of these studies were systematically reviewed and analyzed by meta-analysis.

2. Methods {#sec1-2}
==========

2.1 Search strategy {#sec2-1}
-------------------

Electronic search: we searched in the following Chinese and English databases: Pubmed, Embase, the Cochrane Library, EBSCO, Web of science, Chinese National Knowledge Infrastructure (CNKI), Wanfang Data, VIP, SINOMED, and Airiti Library. The English keywords used for search were schizophrenia, schizophrenia\*, schizophrenic disorders, schizophrenic disorder, dementia praecox, negative symptoms, transcranial magnetic stimulation, TMS, and rTMS. The Chinese keywords were "重复经颅磁刺激", "磁刺激""经 颅磁刺激", "跨颅磁刺激", "精神分裂症", and" 阴性症状". The search deadline for the published studies regarding randomized controlled trials of the rTMS treatment for the negative symptoms of patients with schizophrenia was January 2, 2017. In the search process, we modified the search strategy and keywords according to the requirements of different databases.

We hand-searched the reference lists of the included studies for the discovery of further related research. In addition, we consulted experts in this area as to whether there was any ongoing related research.

2.2 Inclusion and exclusion criteria of literature {#sec2-2}
--------------------------------------------------

This study included randomized controlled trials of rTMS treatment for the negative symptoms of patients with schizophrenia, used the means of systematic review, and evaluated the efficacy and safety of rTMS in the treatment of negative symptoms of schizophrenia.

### 2.2.1 Study type {#sec3-1}

Inclusion of randomized controlled trials: Mock randomized controlled trial. For instance, there was a high risk of bias when implementation was done every other day. This systematic review would include this kind of study. Yet, sensitivity analysis was performed. With an unknown randomization method, cluster randomized and randomized crossover studies would also be included and sensitivity analysis was performed.

### 2.2.2 Study participants {#sec3-2}

Recognized psychiatric diagnostic criteria: (a) The International Classification of Diseases (ICD), (b) the Diagnostic and Statistical Manual of Mental Disorders (DSM), and (c) the Chinese Classification of Mental Disorder (CCMD), diagnosed as schizophrenia.

### 2.2.3 Exclusion criteria {#sec3-3}

The following studies were excluded: (a) non-human studies; (b) narrative review and reporting studies; (c) non-placebo control; (d) research plan; (e) studies of repeated publication.

### 2.2.4 Intervention measures {#sec3-4}

a.  Intervention group

    The intervention group could be one of the following situations: high frequency (the stimulation frequency higher than 1Hz) or low frequency (the stimulus frequency equal to or lower than 1Hz); the stimuli were placed on the left, right, or bilateral dorsolateral prefrontal cortex; rTMS could be combined with other interventions such as drug therapy, psychotherapy, and so forth. Single TMS pulse intervention or studies that had less than 1 week intervention time were excluded.

b.  Control group

    The control group could be one of the following situations: rTMS mock stimulation, electroconvulsive therapy (ECT), drug therapy, psychotherapy, and rTMS treatment with different parameters.

2.3 Literature screening and data extraction {#sec2-3}
--------------------------------------------

The literature screening process of this study is shown in [Figure 1](#fig001){ref-type="fig"}. The literature search was performed independently by two researchers (Junjie Wang, Hong Gan) using the search terms in the electronic databases. All the documents retrieved were managed using EndNote X5 software. The literature was screened by two researchers (Yingqun Zhou, Hong Gan). The first step was to remove repeated studies. The second step was to screen the literature by browsing the literature titles and abstracts according to the inclusion and exclusion criteria. The third step was to read the full text of the selected literature and to confirm included studies by further screening of the literature according to the inclusion criteria and exclusion criteria. If the two search results were different, the two researchers reviewed the literature together and analyzed the reasons for the differences. If the opinions were still inconsistent, a third person (Jiaoyan Pang) would examine and make the final decision. The data extraction table was developed by two researchers (Hui Li, Junjie Wang) for data extraction and verification. The extraction contents included the research publication year, blind method, sample size, age, course of disease, baseline PANSS score evaluation, medication compliance, stimulation site, positioning method, stimulation frequency and intensity, total number of rTMS treatment, control group stimulation model, number of pulses, and the time of follow-up.

2.4 Quality evaluation of literature {#sec2-4}
------------------------------------

Risk of bias evaluation: the RCTs included were assessed by two independent investigators (Yingqun Zhou, Junjie Wang) based on the risk of bias assessment method recommended by the Cochrane manual version 5.3.0. The specific contents included: (a)random sequence generation; (b) allocation concealment; (c) whether to use the blind method (blinding of the subjects and the treatment providers, blinding of the result evaluators); (d) incomplete results data; (e) other potential risks that affected authenticity. When there was discrepancy of options between the 2 researchers, a third person (Hui Li) would make the determination. If the assessment information was lacking, we contacted the corresponding author via e-mail.

Quality of evidence and grades of recommendation: based on the results of the main outcome indicators of the systematic review, the GRADE system recommendation grading method was used to evaluate the quality of evidence. The quality of evidence grades were as follows: (a) high quality: further research was unlikely to affect the reliability of the efficacy evaluation results; (b) medium quality: further research was likely to affect the reliability of the efficacy evaluation results and was very likely to change the outcome of the evaluation; (c) low quality: further research was very likely to affect the reliability of the efficacy evaluation results and the evaluation outcome was very likely to change; (d) extremely low quality: the results of any efficacy evaluation were uncertain.

2.5 Outcome indicators {#sec2-5}
----------------------

### 2.5.1. Main outcome indicators {#sec3-5}

Effectiveness was defined as improvement in negative symptoms. The final outcome assessment scales included in this study were the Scale for the Assessment of Negative Symptoms (SANS) and the negative subscale of PANSS.^\[[@ref21]\]^

### 2.5.2. Secondary outcome indicators {#sec3-6}

a.  Acceptability: including any cause of drop-out.

b.  Safety of rTMS: the differences of adverse effects between rTMS group and control group were compared including severe adverse effects such as epilepsy and mild adverse effects such as headache, dizziness, insomnia, irritation, discomfort or pain at stimulation site, facial spasm and so forth.

2.6 Statistical analysis {#sec2-6}
------------------------

Rev Man 5.3 and Stata 14.0 statistical software were used for meta-analysis. For the extracted continuous and categorical variable data, the simple criteria for statistical analysis of parameters were used based on whether the variables are consistent with normal distribution. When the minimum value was 0, the mean value was larger than twice the standard deviation; if the minimum value was greater than 0, a normal distribution was determined when subtraction of the minimum value from the mean value^\[[@ref27]\]^ was larger than twice the standard deviation. The measurement data were expressed by the adoption of the combined effect as the standardized mean differences (SMD). Count data were shown by using relative risk (RR). The results of the combined calculation were shown in the forest plot. Heterogeneity test was done first. Studies with I^[@ref2]^ (variation statistics of the effect size caused by heterogeneity) \< 50% and *p* ≥ 0.1 in Q test were regarded as having homogeneity; therefore, the fixed effects model was used. When I^[@ref2]^ \> 50% or **p\<** 0.1 in Q test, it explained that actual heterogeneity existed in the study; therefore, the random effects model was used and the source of heterogeneity was analyzed. This study adopted the Cochrane risk of bias assessment tool to evaluate different risk of biases. Subgroup analysis and meta regression analysis were used to explore the sources of heterogeneity based on the factors that might influence heterogeneity in the study. Funnel plot was used to analyze publication bias.

3. Results {#sec1-3}
==========

3.1 Basic characteristics of the included literature {#sec2-7}
----------------------------------------------------

See [figure 1](#fig001){ref-type="fig"} for the process of study inclusion. There were a total of 3500 articles retrieved using relevant search strategies in 5 English databases and 5 Chinese databases, where the articles were published before January 2, 2017. 1835 duplicate studies were removed at first with 1665 articles remaining. During the title and abstract screening phase an additional 1547 articles were removed. Finally, after reading the full text of the remaining 118 articles, we removed 86 of them and were left with 32 articles. However, because the study by Goyal and colleagues ^\[[@ref28]\]^ merely provided the mean value, not the standard deviation, it was excluded as well. In addition, two studies by Hajak (2004) and Cordes (2010) were both excluded for providing change-from-baseline PANSS scores but not final scores. In the end, 29 articles ^\[[@ref15],\ [@ref21],\ [@ref30]\]^ were included in this study for data analysis.

See [table 1](#table001){ref-type="table"} for the characteristics of all final included studies. According to the PANSS, the judging standard was a score of 20 or higher on the symptoms subcale. Except for 7 of the studies, ^\[[@ref16],[@ref26],[@ref29],[@ref30],[@ref32],[@ref35],[@ref48]\]^ the included patients with schizophrenia in most of the studies mainly had negative symptoms. Patients took antipsychotics before treatment and the original drug treatment was unchanged during the treatment process. Therefore, all the studies were combined with rTMS as a synergistic treatment. The time for followup was mostly 2 weeks after treatment. The smallest study sample size was 17 cases; ^\[[@ref17]\]^ the largest was 117 cases. ^\[[@ref24]\]^ The smallest mean age was 26 years^\[[@ref22]\]^ and the oldest was 56.^\[[@ref21]\]^

In terms of treatment parameters, the stimulation sites were the following: other than 2 studies, most of the studies used high frequency stimulation on the left dorsolateral prefrontal cortex. The stimulation site of the study of Garg and colleagues was the speech function in the cerebellum. Frequency of stimulation: most used high frequency stimulation, however, there were 5 studies ^\[[@ref21],\ [@ref22],[@ref26],[@ref38],[@ref39]\]^ using transcranial magnetic stimulation with thet a burst stimulation. The course of treatment: 2 weeks, 3 weeks, or 4 weeks; other than Lange 2015^\[[@ref50]\]^ there was one study that had stimulation treatment daily. Except for the 2 studies by Gan,^\[[@ref22],\ [@ref42]\]^ other control groups used mock stimulation as the control study. Nevertheless, there were differences in method of mock stimulation. Most of them chose a mock stimulus coil or flipped the magnetic coil.

3.2 Research quality {#sec2-8}
--------------------

The results of the quality assessment are shown in [figure 2](#fig002){ref-type="fig"} and [table 2](#table002){ref-type="table"}. Only 7 out of the 29 studies did not describe the random sequence generation in detail resulting in a rating of "unable to determine".^\[[@ref15],\ [@ref22],[@ref29],[@ref32],[@ref34]\]^ The method of random sequence generation was provided in 22 studies resulting in a rating of "low risk". There were 15 studies^\[[@ref17],[@ref26],[@ref36],[@ref42],[@ref51]\]^ that described the specific implementation process of the blinded method for participants. Except the 3 studies^\[[@ref22],\ [@ref34],\ [@ref46]\]^ that did not describe the blinding of the evaluators, the evaluation of the negative symptom outcome indicators were assessed by the evaluators using the blind method in all other studies. The loss to follow-up bias in one study^\[[@ref26]\]^ was rated as "high risk" because the drop-out rate of this study was larger than 20% and the intentionto-treat analysis was not implemented. There were 5 studies^\[[@ref15],[@ref16],[@ref29],[@ref30],[@ref42]\]^ that reported incomplete data due to drop-out and adverse effects.

See [figure 2](#fig002){ref-type="fig"} for the funnel plot of the main treatment efficacy outcome indicators given by the 29 studies. The asymmetry of the funnel plot asymmetry may be due to publication bias, but there may also be other factors leading to the asymmetry.

3.3 Treatment effect {#sec2-9}
--------------------

In the 29 studies, only 1 study assessed the efficacy of the negative symptoms with the SANS scale.^\[[@ref33]\]^ The rest of the studies provided data from the PANSSnegative subscale, which included 1400 participants. The heterogeneity of the included studies was high. The random effect model was used when I^[@ref2]^ was 73%, SMD= -0.40, and 95%CI= -0.62\~-0.18. As shown in [figure 3](#fig003){ref-type="fig"}, the efficacy of the synergistic rTMS treatment on negative symptoms in schizophrenia had a weak effect. According to the GRADE evaluation criteria, the overall evidence quality level for the primary outcome indicator, which was the improvement of negative symptoms at the end of the rTMS treatment, was "moderate". See [table 3](#table003){ref-type="table"}.

Heterogeneity of results may be due to differences across studies in patients' negative symptom severity and differences in stimulation methods. Therefore, we used meta-regression to assess the relationship between the above factors and the source of heterogeneity. In addition, we also included age and course of disease as possible regulatory variables into the meta-regression model to analyze the effects of these two factors on heterogeneity. The results showed that, conducting separate meta-regression analysis on the above mentioned 4 factors, the regression model of the treatment efficacy and the baseline PANSS negative symptom score found that **t**=-2.23, **p**=0.035, indicating the severity of the negative symptoms were one of the sources of heterogeneity. After putting the severity of the negative symptoms into the meta regression model, the variance component of the study was reduced from 0.26 to 0.25, showing that 3.85% of the source of heterogeneity could be explained. The regression models of treatment efficacy, rTMS method, course of disease, and age respectively found **t**=0.89, **p**=0.381; **t**=1.20, **p**=0.245, and **t**=-0.38, **p**=0.709, indicating that the association of these 3 factors and heterogeneity among the studies were not statistically significant. After placing the four factors into the meta-regression model simultaneously, the variance component of the study was reduced from 0.26 to 0.19, showing that 26.92% of the source of heterogeneity could be explained. [Figure 4](#fig004){ref-type="fig"} was the meta-regression analysis of the standardized mean difference (SMD) of the rTMS combined with antipsychotic drugs for the treatment of negative symptoms and the baseline PANSS negative symptom score.

3.4 Acceptability {#sec2-10}
-----------------

There were 28 studies that reported dropouts and the total sample size was 1492 cases. The heterogeneity of the studies was low. Fixed effect model was selected because I^[@ref2]^ was 0%. The analysis results showed that RR= 0.75, 95%CI= 0.49\~1.15. As the group that used synergistic treatment for the negative symptoms of schizophrenia, rTMS had no difference in the acceptability to the control group, as shown in [figure 5](#fig005){ref-type="fig"}. In addition, the GRADE evidence quality of the outcome indicator was rated as "low level", as shown in [table 3](#table003){ref-type="table"}.

3.5 Adverse effects {#sec2-11}
-------------------

There was no report of severe adverse events in all included studies. There were 19 studies which had mild adverse effect induced by rTMS. There were reports on the specific adverse effects of 1296 schizophrenic patients in addition to the reports on the total number of cases with adverse effects. The adverse effects reported included headache, dizziness, pain in the stimulated area, facial spasm, and insomnia. The meta-analysis of the results showed that rTMS for the treatment of negative symptoms had a higher incidence of adverse effects: RR= 2.20, 95%CI= 1.53\~ 3.18. Moreover, the heterogeneity was low (I^[@ref2]^ =0), as shown in [figure 6](#fig006){ref-type="fig"}. However, the evidence quality of these studies was rated as "low level" ([table 3](#table003){ref-type="table"}).

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-12}
-----------------

There were less treatment options for the negative symptoms of patients with schizophrenia. Although there have been several systematic reviews that assessed the efficacy of rTMS treatment, the development of new treatment paradigms in recent years and the increase of studies with large sample sizes may have supplemented or changed the conclusions of the previous systematic reviews. The aim of this study was to evaluate and update the efficacy and safety of the rTMS treatment on negative symptoms of schizophrenia.

We screened 29 RCTs studies with major outcome indicators from both English and Chinese databases, including 12 English articles and 17 Chinese articles. The studies that had a large sample size and long course of treatment were mostly Chinese. Based on the metaanalysis results of 1440 cases, antipsychotic treatment combined with the rTMS treatment may improve the negative symptoms of patients with schizophrenia. Based on the risk of bias assessment of a single study, the evidence quality GRADE rating of the primary outcome indicator (efficacy) was "moderate level", meaning that the outcome indicator result was a weak recommendation for supporting the use of rTMS intervention. In terms of acceptability and adverse effects, rTMS had better acceptability and no serious adverse effect.

4.2 Limitations {#sec2-13}
---------------

The quality of the RCT studies included in this systematic review was high. The evaluators were blinded. However, the heterogeneity of our main outcome indicators was high. Further meta regression analysis showed that the severity of negative symptoms when first entered into the group might possibly be the source of heterogeneity. In addition, differences in the rTMS treatment methods in the included studies such as the intensity of stimulation, the total number of pulses, and so forth, may also be a source of heterogeneity.

4.3 Implications {#sec2-14}
----------------

This study conducted evaluation of RCT studies of rTMS combined with antipsychotics in the treatment of the negative symptoms of schizophrenia, discovering that the use of rTMS had a relatively weak effect on the improvement of negative symptoms. Although its use had good acceptability, the treatment might induce adverse effects such as dizziness, headache, and so forth. For patients with schizophrenia who have persistent negative symptoms, the use of rTMS might be considered clinically. However, we should be cautious in the interpretation of the results due to the high heterogeneity of the studies. Further studies are needed to determine the optimal mode of treatment, such as stimulation frequency, stimulation intensity, duration of treatment, and total pulse number.

The authors thank the translators and reviewers of this article.

**Funding**

Shanghai Municipal Health and Family Planning Commission research project (project code: 20134282); Science and Technology Commission of Shanghai Municipality project (project code: 16411965000); Shanghai Hospital Development Center (SHDC12014111); Shanghai Key Laboratory of Psychotic Disorders (13dz2260500)

**Conflict of interest statement**

The authors declare no conflict of interest related to this manuscript.

**Authors' contributions**

Junjie Wang and Hong Gan were responsible for the literature search.

Hong Gan, Yingqun Zhou, and Jiaoyan Pang were responsible for article selection.

Hui Li and Junjie Wang were responsible for data extraction.

Junjie Wang, Yingqun Zhou, and Hui Li were responsible for risk of bias assessment.

Junjie Wang and Hui Li were responsible for statistical analysis.

Hui Li and Junjie Wang were responsible for writing up the article.

Jijun Wang and Chunbo Li were responsible for planning and guidance.

![](sap-29-61-g007.gif)

Junjie Wang graduated at Jining Medical University in 1998 with her bachelor's degree in Medicine and graduated from Shanghai Jiaotong University School of Medicine with her master's degree in 2003. In 2014, she was accepted into the Shanghai Jiaotong University School of Medicine and did her doctorate at the Shanghai Mental Health Center with a concentration in psychiatry and mental health. Her main research interests are the pathogenesis and early intervention for schizophrenia.

![](sap-29-61-g008.jpg)

**"The 14^th^ annual academic conference of the Chinese Society of Neuroscience & Psychiatry"**, which is hosted by CSNP, and undertaken by Mental Health Center of Shanghai Jiao Tong University's medical school and Shandong Mental Health Center, will be held in the Luneng Hilton Hotel in Jinan, Shandong, from 29^th^ June to 1^st^ July, 2017.

The present society welcomes paper submissions and conference participations. The conference affair group accepts abstracts (objectives, methods, results and conclusions) under 1000 words. The website used for paper submissions and registrations is <http://61.147.124.137:8088/2017/default.aspx.> The academic committee of this conference will review papers and select high quality reports for presentation at the conference. We look forward to your participation and support! The deadline for paper submission is 1^st^ June, 2017.

We welcome colleagues from all over China and abroad to participate in this conference held in scenic Jinan. We are looking forward to a lively discussion on developments in the field.

**Dates:** 29^th^ June to 1^st^ July, 2017 (check in on 29^th^ June)

**Address:** Luneng Hilton Hotel in Jinan, Shandong, No.2888 South Erhuan Lu, Central District in Jinan

**Cost arrangement:** The registration fee, travel fee and accommodation fee are at your own expense. The registration fee is 1000 yuan (Shandong representatives and graduate students with student IDs can pay half of the registration fee). The accommodation fee from 30^th^ June to 1^st^ July 2017 is 500 yuan per standard room.

**Contact:** Ruizhi Mao 18221768225

**E-mail:** <csnpmeeting@163.com>

**Chinese Society of Neuroscience & Psychiatry**

**4^th^ February 2017**

![Flowchart of the literature search and screening](sap-29-61-g001){#fig001}

![Funnel plot of potential publication bias of the efficacy of antipsychotics combined with rTMS in the treatment of the negative symptoms of schizophrenia](sap-29-61-g002){#fig002}

![Forest plot of efficacy of antipsychotic drugs combined with rTMS in treatment of negative symptoms in schizophrenia](sap-29-61-g003){#fig003}

![Meta-regression analysis of the standardized mean difference (SMD) of the TMS combined with antipsychotic drugs for the treatment of negative symptoms and the baseline PANSS negative symptom score](sap-29-61-g004){#fig004}

![Efficacy of antipsychotic drugs combined with rTMS in the treatment of negative symptoms of schizophrenia: drop outs](sap-29-61-g005){#fig005}

![Adverse effects of antipsychotic drugs combined with the rTMS in treatment of negative symptoms of schizophrenia forest plot](sap-29-61-g006){#fig006}

###### 

The basic characteristics of the included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies                         Blinded Method    Sample size TMS group Control group   Age Mean (SD) TMS group Control group   Course of disease Mean (SD) TMS group Control group   Baseline PANSS Mean (SD) TMS group Control group   Stimulation site[^abde^](#tfn001){ref-type="table-fn"}, Positioning method   Stimulation frequency Stimulation intensity                             Treatment frequency, Number of pulses each time
  ------------------------------- ----------------- ------------------------------------- --------------------------------------- ----------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------
  Klein 1999^\[[@ref29]\]^        Double blind      18\                                   30.2 (10.0)\                            7.9 (8.6)\                                            16.5(5.6)\                                         R-PFC\                                                                       1Hz\                                                                    10 times\
                                                    17                                    29.5 (9.3)                              7.9 (8.7)                                             14.1(5.0)                                          -                                                                            110%                                                                    -

  Holi 2004^\[[@ref15]\]^         Single blind      11\                                   38.5(10.2)\                             13.5(8.9)\                                            28.9(11.5)\                                        L-DLPFC\                                                                     10Hz\                                                                   10 times\
                                                    11                                    34.8(9.8)                               12.9(12)                                              31.0(7.7)                                          -                                                                            100%                                                                    -

  Novak 2006^\[[@ref16]\]^        Double blind      9\                                    35(9.2)\                                13.1(8.1)\                                            20 (5.9)\                                          L-DLPFC\                                                                     20Hz\                                                                   10 times\
                                                    9                                     32.8(6.3)                               9.9(4.1)                                              20.5(3.3)                                          -                                                                            90%                                                                     2000 pulses

  Xu 2006^\[[@ref36]\]^           Double blind      frontal lobe 21,22\                   36.2(13.7)\                             12.1(10.1)\                                           22.3(7.8)\                                         B-DLPFC\                                                                     Confirmation of frequency according to the main frequency of EEG, 80%   10 times\
                                                    parietal lobe 12,12                   37.6(14.6)\                             12.0(10.2)\                                           22.1(5.8)\                                         Bilateral parietal lobe                                                                                                                              -
                                                                                          34.3(10.6)\                             13.3(9.9)\                                            23.1(6.7)\                                                                                                                                                                                              
                                                                                          45.6(14.1)                              21.0(11.8)                                            23.6(7.6)                                                                                                                                                                                               

  Mogg 2007^\[[@ref17]\]^         Double blind      8\                                    50.8 (14.5)\                            25 (16.7)\                                            29.8 (3.0)\                                        L-DLPFC\                                                                     10Hz\                                                                   10 times\
                                                    9                                     33.6 (9.8)                              9 (7.9)                                               29.1 (2.6)                                         -                                                                            110%                                                                    2000 pulses

  Fitzgerald 2008^\[[@ref30]\]^   Double blind      12\                                   37.2(10.4)\                             Not provided                                          16.8(3.5)\                                         L-DLPF MC moves forward 5CM                                                  10Hz\                                                                   15 times\
                                                    8                                     33.2(9.8)                                                                                     18.6(6.4)                                                                                                                       110%                                                                    2000 pulses

  Liu 2008^\[[@ref37]\]^          Double blind      13\                                   34.5(13.0)\                             5.10(4.15)\                                           24.9(7.3)\                                         L-DLPFC\                                                                     10Hz\                                                                   20 times\
                                                    12                                    34.4(8.2)                               7.83(5.3)                                             20.6(8.1)                                          -                                                                            110%                                                                    1500 items

  Zhang 2010\[^38\]^              Double blind      15\                                   37(11)\                                 16(12.6)\                                             25.7(3.1)\                                         L-DLPFC\                                                                     TBS mode\                                                               20 times\
                                                    15                                    39(14)                                  12(8.7)                                               26.9(2.9)                                          -                                                                            80%                                                                     2400 pulses

  Ren 2011^\[[@ref40]\]^          Double blind      12\                                   31(7)\                                  8.2(3.8)\                                             28.2(6.8)\                                         B-DLPFC\                                                                     20Hz\                                                                   10 times\
                                                    11                                    37.7(12.3)                              8.9(4.2)                                              23.7(6.2)                                          F3,F4                                                                        80%                                                                     800 items

  Chen 2011^\[[@ref39]\]^         Double blind      24\                                   37.4(11.8)\                             17(12.6)\                                             25.9(3.2)\                                         L-DLPFC\                                                                     iTBS mode\                                                              20 times\
                                                    22                                    39.7(13.3)                              13(12.6)                                              26.9(2.5)                                          -                                                                            80%                                                                     2400 pulses

  Barr 2012^\[[@ref32]\]^         Double blind      13\                                   40.5(12.2)\                             18.6(11.3)\                                           14.9(6.4)\                                         L-DLPFC Neuronavigation technique                                            20Hz\                                                                   20 times\
                                                    12                                    47.9(12.8)                              27.3(16.4)                                            15.5(6.3)                                                                                                                       90%                                                                     750 pulses

  Zheng 2012™                     Double blind      TBS 18\                               56.4(9.3)\                              \-                                                    23.6(5.4)\                                         L-DLPFC\                                                                     TBS mode 10Hz\                                                          10Hz and 20Hz group: 5 times /1200 pulses TBS group: 5times/400 pulses
                                                    10 Hz19\                              56.5(7.4)\                                                                                    23.3(4.9)\                                         -                                                                            20 Each groups was 80%                                                  
                                                    20Hz 19\                              56.8(5.4)\                                                                                    23.7(5.4)\                                                                                                                                                                                              
                                                    17                                    55.6(5.8)                                                                                     22.8(5.1)                                                                                                                                                                                               

  Prikryl 2013^\[[@ref33]\]^      Double\           23\                                   31.6 (8.0)\                             4.9 (5.1)\                                            \-                                                 L-DLPFC\                                                                     10Hz\                                                                   15 times\
                                  blind             17                                    33.9(10.0)                              5.9 (7.9)                                                                                                MC moves\                                                                    110%                                                                    2000 pulses
                                                                                                                                                                                                                                           forward 5CM                                                                                                                                          

  Duan 2013^\[[@ref41]\]^         Double blind      21\                                   26.6(7.2)\                              4.8(2.5)\                                             22.3(3.1)\                                         L-DLPFC\                                                                     10Hz\                                                                   20 times\
                                                    20                                    27.3(8.5)                               4.5(2.6)                                              22.6(3)                                            F3 of 10/20                                                                  100%                                                                    -

  Gan 2014a^\[[@ref22]\]^         Double blind      20\                                   26(8)\                                  5.4(2.7)\                                             22.9(3.6)\                                         L-DLPFC\                                                                     TBS mode\                                                               20
                                                    21                                    27(7)                                   4.8(2.5)                                              22.3(3.1)                                          F3 of 10/20                                                                  100%                                                                    

  Gan 2014b^\[[@ref42]\]^         Single blind      38\                                   27.4(8.6)\                              5.1(2.3)\                                             22.8(6.6)\                                         L-DLPFC\                                                                     10Hz\                                                                   20
                                                    37                                    26.9(7.5)                               4.7(2.1)                                              22.3(6.8)                                          F3 of 10/20                                                                  100%                                                                    

  Rabany 2014^\[[@ref34]\]^       Double blind      20\                                   33.1(11.3)\                             \-                                                    22.7(8.4)\                                         L-DLPFC\                                                                     20Hz\                                                                   20 times\
                                                    10                                    35.9(11.0)                                                                                    20.1(3.6)                                          MC moves forward 5CM                                                         120%                                                                    1680 pulses

  Zhao 2014^\[[@ref43]\]^         Single blind      TBS 24\                               47.7(11.8)\                             \-                                                    38.7(7.4)\                                         L-DLPFC\                                                                     10Hz(80-110%)\                                                          10 and 20 Hz groups: 20 times /1500; TBS group: 20 times /2400 pulses
                                                    10Hz 24\                              48(12.2)\                                                                                     37.6(5.1)\                                         -                                                                            20Hz(80-110%)\                                                          
                                                    20Hz 23\                              49.1(10.6)\                                                                                   36.2(8.8)\                                                                                                                      TBS(80%)                                                                
                                                    22                                    46.7(13.1)                                                                                    38.6.7(2.1)                                                                                                                                                                                             

  Quan 2015^\[[@ref24]\]^         Double blind      78\                                   46.9 (7.9)\                             20.5(11.0)\                                           26.2(3.6)\                                         L-DLPFC MC moves forward 5CM                                                 10Hz 80%                                                                10 times\
                                                    39                                    46.9 (9.1)                              18.0(11.0)                                            27.0(4.4)                                                                                                                                                                                               800 pulses

  Lange 2015^\[[@ref35]\]^        Double blind      16\                                   41.8(11.6)\                             15.6(10.1)\                                           20.6(3.7)\                                         Bilateral DLPFC F3 and F4                                                    10Hz 90%                                                                30 times\
                                                    16                                    32.3(9.7)                               9.92(8.9)                                             19.7(5.4)                                                                                                                                                                                               2000 pulses

  Xu 2015^\[[@ref23]\]^           evaluator blind   5Hz 30\                               44.4(6.2)\                              11.8(3.6)\                                            26.0(3.2)\                                         L-DLPFC\                                                                     5Hz 10Hz Both groups were 80%                                           10 times\
                                                    10Hz 30\                              46.8(6.7)\                              11.6(3.7)\                                            25.33(2.6)\                                        -                                                                                                                                                    2500 pulses
                                                    30                                    44.7(4.3)                               12.8(3.5)                                             25.2(2.7)                                                                                                                                                                                               

  Bai 2015^\[[@ref44]\]^          Single blind      36\                                   35.4(7.1)\                              25.4(7.3)\                                            28.8(4.0)\                                         L-DLPFC\                                                                     10Hz 100%                                                               20 times 800 pulses
                                                    35                                    34.6(6.3)                               27.1(4.2)                                             29.3(3.9)                                          -                                                                                                                                                    

  Gan 2015^\[[@ref49]\]^          Single blind      32\                                   28(9)\                                  4.5(2.9)\                                             22(6)\                                             L-DLPFC\                                                                     10Hz 100%                                                               20 times\
                                                    35                                    29(9)                                   4.9(2.9)                                              25.2(2.7)\                                         -                                                                                                                                                    4000 pulses
                                                                                                                                                                                        22(6)\                                                                                                                                                                                                  
                                                                                                                                                                                        25.2(2.7)                                                                                                                                                                                               

  Wang 2015^\[[@ref45]\]^         Double blind      41\                                   42.5(5.6)\                              5.9(2.4)\                                             26.6(4.1)\                                         L-DLPFC\                                                                     10Hz 110%                                                               20 times\
                                                    42                                    42.0(5.9)                               6.2(2.7)                                              26.8(3.3)                                          -                                                                                                                                                    2400 pulses

  Zhang 2015^\[[@ref46]\]^        Single blind      35\                                   40.7(9.8)\                              5.2(3.0)\                                             29.4(2.1)\                                         L-DLPFC\                                                                     10Hz -                                                                  20 times\
                                                    34                                    39.1(8.8)                               5.89(3.1)                                             28.5(2.3)                                          -                                                                                                                                                    800 pulses

  Tikka 2016^\[[@ref26]\]^        evaluator blind   10\                                   28.4(2.9)\                              3.6(1.2)\                                             17.5(5.6)\                                         R-IPL^e^ MRI navigation                                                      cTBS 5Hz 120%                                                           10 times\
                                                    10                                    25.5(5.0)                               3.5(1.1)                                              17.1(5.5)                                                                                                                                                                                               900 pulses

  Garg 2016^\[[@ref25]\]^         Double blind      20\                                   32.4(8.4)\                              7.2(7.5)\                                             25.3(8.0)\                                         Below occipital protuberance 1CM                                             TBS 100%                                                                10 times\
                                                    20                                    37.2(7.9)                               6.1(5.6)                                              20.6(9.2)                                                                                                                                                                                               600 pulses

  Li 2016^\[[@ref47]\]^           Double blind      25\                                   45.2(10.2)\                             19.7(2.2)\                                            27.2(7.6)\                                         L-DLPFC\                                                                     10Hz\                                                                   20 times
                                                    22                                    44.9(10.6)                              19.9(2.3)                                             25.9(7.2)                                          -                                                                            110%                                                                    

  Ma 2016^\[[@ref48]\]^           Double blind      58\                                   \-                                      \-                                                    19.6(3.8)\                                         L-DLPFC\                                                                     10Hz 90%                                                                20 times\
                                                    60                                                                                                                                  20.9(4.7)                                          -                                                                                                                                                    1000 pulses
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a\. F3 and F4: Electrode placement location of the International 10--20 system

b\. L-DLPFC: left dorsolateral prefrontal cortex; R-DLPFC: right dorsolateral prefrontal cortex; B-DLPFC: bilateral right dorsolateral prefrontal cortex

c\. cTBS: continuous theta burst stimulation; iTBS: intermittent theta burst stimulation

d\. MC: motor cortex; e. R-IPL: inferior parietal lobule; f. SD: standard deviation; g. no data or not described

###### 

Risk of bias assessment based on the Cochrane risk of bias assessment tool for the 29 included studies

  Studies                         Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias
  ------------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------
  Klein 1999^\[[@ref29]\]^        Unclear                      Unclear                  Unclear                                  Low                              Unclear                   High                  Low
  Holi 2004^\[[@ref15]\]^         Unclear                      Low                      Unclear                                  Low                              Unclear                   High                  Unclear
  Novak 2006^\[[@ref16]\]^        Unclear                      Unclear                  Unclear                                  Low                              Unclear                   High                  Low
  Xu 2006^\[[@ref36]\]^           Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Mogg 2007^\[[@ref17]\]^         Unclear                      Low                      Unclear                                  Low                              Low                       Low                   Low
  Fitzgerald 2008^\[[@ref30]\]^   Low                          Low                      Unclear                                  Low                              Unclear                   Low                   Unclear
  Liu 2008^\[[@ref37]\]^          Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Zhang 2010^\[[@ref38]\]^        Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Ren 2011^\[[@ref40]\]^          Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Chen 2011^\[[@ref39]\]^         Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Barr 2012^\[[@ref32]\]^         Unclear                      Unclear                  Unclear                                  Low                              Low                       Low                   Low
  Zheng 2012^\[[@ref21]\]^        Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Prikryl 2013^\[[@ref33]\]^      Low                          Unclear                  Low                                      Low                              Unclear                   Unclear               Low
  Duan 2013^\[[@ref41]\]^         Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Gan 2014a^\[[@ref22]\]^         Unclear                      Unclear                  Unclear                                  Unclear                          Low                       High                  Low
  Gan 2014b^\[[@ref42]\]^         Low                          Low                      Unclear                                  Low                              Low                       Low                   Low
  Rabany 2014^\[[@ref34]\]^       Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Low                   Low
  Zhao 2014^\[[@ref43]\]^         Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Quan 2015^\[[@ref24]\]^         Low                          Unclear                  Low                                      Low                              Unclear                   Unclear               Low
  Lange 2015^\[[@ref35]\]^        Low                          Low                      Unclear                                  Low                              Unclear                   Low                   Low
  Xu 2015^\[[@ref23]\]^           Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Bai 2015^\[[@ref44]\]^          Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Low
  Gan 2015^\[[@ref49]\]^          Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Low
  Wang 2015^\[[@ref45]\]^         Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Zhang 2015^\[[@ref46]\]^        Low                          Unclear                  Unclear                                  Unclear                          Low                       Low                   Unclear
  Tikka 2016^\[[@ref26]\]^        Low                          Low                      Low                                      Low                              Low                       Low                   Low
  Garg 2016^\[[@ref25]\]^         Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Low
  Li 2016^\[[@ref47]\]^           Low                          Unclear                  Low                                      Low                              Low                       Low                   Low
  Ma 2016^\[[@ref48]\]^           Low                          Unclear                  Low                                      Low                              Low                       Low                   Low

^a^ Other biases considered included the bias of the study specificity and false research results

^b^ If these 7 items were evaluated as "low", the overall bias was evaluated as a "low risk of bias "; If there was at least one "Unclear" and the rest were "low", this study was "unable to evaluate the risk of bias"; If there was any aspect evaluated as "high", this study was "high risk of bias"

###### 

Summary of the quality GRADE rating of different outcome indicators in randomized controlled trials and the meta analysis results of antipsychotic drugs combined with rTMS in the treatment of negative symptoms of schizophrenia

  Outcome              Number of Study (including sample size)   Heterogeneity test   Analysis model   Group effect test   Estimated value^[a](#tfn002){ref-type="table-fn"}^   95% CI of the estimated value   GRADE ^[b](#tfn003){ref-type="table-fn"}^                  
  -------------------- ----------------------------------------- -------------------- ---------------- ------------------- ---------------------------------------------------- ------------------------------- ------------------------------------------- -------------- --------
  Clinical efficacy    1440                                      73%                  \<0.001          Random effect       3.56                                                 \<0.001                         -0.40 (SMD)                                 -0.62, -0.18   Medium
  Drop-out situation   1492                                      0%                   0.98             Fixed effect        1.32                                                 0.19                            0.75 (RR)                                   0.49, 1.15     Low
  Adverse effect       1296                                      0%                   0.73             Fixed effect        4.23                                                 \<0.001                         2.20(RR)                                    1.53, 3.18     Low

^a^Standardized mean difference was used in the comparison of continuous variables; Risk ratios of categorical variables (RR)

^b^The use of Grades of Recommendation Assessment Development and Evaluation to rate each result's evidence quality
